Genetic kuyedza kenza yemudumbu
After nearly ten years of development, tumor genetic testing has become the immediate need of a large number of cancer patients. The test report guidance provided by tumor genetic testing perfectly fits the development concept of precision medicine, and has penetrated into all aspects of the diagnosis and treatment of tumor patients. For patients, they can choose targeted drugs for precise treatment, avoid detours, and avoid unnecessary side effects. bitter.
Ikozvino mamiriro ekurapa kwakanangwa kwekenza yemudumbu
In most cases, surgery is still the main treatment for gastric cancer. However, the heterogeneity of gastric cancer is very strong, and its biological behavior is affected by the huge gene regulation in the cell. Therefore, only by classifying the essential characteristics of gastric cancer from the molecular level can early diagnosis and prognosis judgment of the tumarara be more reasonable and accurate , Application of molecular targeted drugs for individualized and precise treatment of patients.
Parizvino, zvinotevera zvinodhaka zvakanangwa zvakagamuchirwa.
| Siriyero nhamba | chipfuro | chiremba |
| 1 | HER2 | Trastuzumab (Trastuzumab, Herceptin) |
| 2 | VEGFR | Ramucirumab |
| 3 | NTRK | Larotrectinib (LOXO-101) |
| 4 | PD-1 | Pembrolizumab (K drug) |
| 5 | VEGFR-2 | Apatinib (Apatinib, Aitan) |
In addition, there are many other targeted drugs related to gastric cancer in clinical trials, such as drugs that block HER2: lapatinib (Tykerb ®), pertuzumab (Perjeta ®) and trastuzumab emtansine (Kadcyla ®). Drugs that block EGFR: Panitumumab (Victibi®) is a drug that targets EGFR that is being tested for gastric cancer.
The Global Oncologist Network reminds everyone that genetic testing is required before targeted therapy . Only by understanding the type of tumor gene mutation can a reasonable treatment plan be developed to benefit patients. In addition, in the selection of genetic testing technology, it is necessary to select the appropriate testing technology according to its corresponding target . Only by choosing products approved by the State Food and Drug Administration can the accuracy and reliability of the test results be guaranteed.
Varwere vane gomarara remudumbu vanosarudza sei kuongorora majini?
The Global Oncologist Network reminds patients that cancer genetic testing and clinical treatment analysis are a systematic project that requires strong laboratory support, high-standard testing quality control and a high-level data analysis team. A good genetic test analysis can avoid the loss of treatment opportunities and save the lives of cancer patients. At present, there are dozens of genetic testing institutions on the market, and patients must carefully select genetic testing companies to ensure the accuracy of the test results.
Heino tekinoroji yekuyedza genetiki inogamuchirwa neDFA!
HwaroOne®CDx
FoundationOne®CDx yakatenderwa neDFA seyekutanga pan-bundu mhando inosangana yekuongorora chigadzirwa . As a research tool, it assisted the discovery of countless scientific research results, and accumulated a large amount of data during this period. The current test coverage includes 324 genes and two molecular markers (MSI / TMB) that can predict the efficacy of immune checkpoint inhibitors. It can cover all solid tumors (except sarcoma) and can directly correspond to 17 mishonga yakanangwa inogamuchirwa neDFA!
For clinical evaluation of cancer genes, commonly used techniques include Sanger sequencing, mass spectrometry genotyping, fluorescence in situ hybridization (FISH) and immunohistochemical analysis (IHC). “Standard single marker detection” such as FISH, IHC and multi-gene hotspot detection (hotspot panel) can only find one or two types of clinically significant genetic abnormalities (such as only base substitutions). Studies have shown that the latest comprehensive next-generation sequencing technology for cancer comprehensive genetic testing can detect all four types of genetic abnormalities (base replacement; insertion and deletion; copy number variation and rearrangement), and is more accurate than traditional, standard tests.
Varwere vegomarara vanogona sei kuongorora FoundationOne® CDx kuyedzwa?
MuChina, iri basa rekuongorora rakapihwa naDean Diagnostics. Global Oncologist Network inogona kubatsira varwere vegomarara kuti vagamuchire sevhisi, kana kuongororwa kwemajini kwechitupa chemvumo yekumba. Global Oncologist Network, senzvimbo inozivikanwa yecancer yevarwere yepuratifomu, yanga iri iyo oncology nzvimbo uye vanozivikanwa gomarara nyanzvi vanoshanda pamwe chete kugara vachironga misangano mikuru yekuchinjana chiremba-murwere uye hurukuro dzakakurumbira dzesainzi kubatsira varwere kuwana zvakaenzana. uye zvine chiremera kuongororwa uye zvirongwa zvekurapa kuburikidza nekubvunzurudzwa kwehunyanzvi kumba nekune dzimwe nyika, uye nekuvandudza mwero wekupora. Tichaitawo kuedza kusingagumi kuenderera mberi tichizivisa nyika inotungamira inorwisa kenza ruzivo, tekinoroji, nyanzvi, madhiragi, kuyedzwa kwekiriniki, nezvimwewo, uye nekuedza kwese kupa varwere vazhinji vane zvirinani mabasa ekurwisa gomarara.
CancerFax se inozivikanwa inozivikanwa kenza yemudzimba kuongororwa uye kurapwa kurapwa uye webasa chikuva, yakazvipira kupa yekutanga-kirasi anti-gomarara masevhisi kune epamba varwere kenza, kusanganisira yazvino inorwisa kenza tekinoroji uye yepamusoro kenza nyanzvi zviwanikwa, kumisikidza iro rakakura bundu kubvunza uye kubvunza nzvimbo muIndia, uye Kubatana pamwe neakakurumbira bundu kubvunza nzvimbo uye nyanzvi muUnited States, China, Israel, uye Europe kuti ive yakavimbika kupfuura bundu kuongororwa uye kurapwa kurapwa nyanzvi munyika.
